L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
For North America
Dr. Danielle Marcoux from Canada
Camp Liberté – Summer camp for children with skin disorders
This one-week summer camp run by volunteer dermatologists and nurses enrolled children aged 7 to 12 with moderate-to-severe skin disorders, as well as their families, to bring them together for support, social interaction and to increase their confidence. All the activities aim to increase patients’ confidence and self-esteem, improve social skills, reduce stigma about their condition and improve adherence to treatment.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
Dr. Ksenia Sorokina from Russia
A healthy child means a healthy family- Targeting prevention of dermatitis and adherence to treatment
This project consists of providing training workshops for parents and children with chronic skin diseases and developing the first ever website to allow patients living in remote areas of the Russian Federation to access a consultation with a dermatologist, as well as attend online training seminars for people presenting chronic dermatitis and to increase adherence to therapy for patients as well as their parents, within four Russian territories.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
For Africa and Arab States
Prof. Khalid Mohammed AlGhamdi from Saudi Arabia
Charity Society known as Faal to empower and support vitiligo patients in Saudi Arabia
Vitiligo is a long-term skin condition that causes pale, white patches on the skin due to a lack of melanin. This project aimed to increase awareness via TV broadcasts, schools visits and to provide psychological and social support to patients with vitiligo through training courses and different education programs.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, announced today the launch of its Hidden ScarTM Surgery program designed to certify surgeons and establish Centers of Excellence at major cancer centers and hospitals across the country. This innovative program will train surgeons on advanced minimally invasive and minimal access surgical approaches that deliver optimal clinical and aesthetic outcomes for patients. As part of the company’s broader women’s health initiative, Invuity is hosting a Hidden Scar Breast Cancer Surgery training course in advance of the American College of Surgeons (ACS) Clinical Congress.
Invuity aims to transform the surgical treatment of breast cancer with this advanced surgical approach for nipple sparing mastectomies and lumpectomies (breast conserving surgery). Hidden Scar Breast Cancer Surgery expands surgical options for patients, offering superior cosmetic outcomes that can improve their psychological and emotional recovery and enhance quality of life after surgery.1
With growing demand for less invasive alternatives to breast cancer surgery, surgeons need to operate through smaller incisions with limited fields of vision. Invuity’s illumination technology allows surgeons to access and visualize the entire breast cavity through discrete incision locations, enabling surgeons to safely and effectively treat breast cancer while preserving the natural shape of the breast and thereby minimizing and hiding the scars.
To view the multimedia release go to:
http://www.multivu.com/players/English/7644051-invuity-hidden-scar-breast-cancer-surgery-program/
Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today the international launch of the new PicoWay™ picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a state-of-the-art dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos, including recalcitrant tattoos. The staged launch of PicoWay begins in the international market during October 2014 and will continue in the United States in the first half of 2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762556-syneron-launch-picoway-picosecond/
Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily1.
Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes2-4.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control
Varsity Brands, the recognized leader in team athletic gear, the driving force in cheerleading and dance, and the most trusted name in celebrating student milestones, today announced Vista Murrieta High School, from Murrieta, Calif. as the winner of its America’s Most Spirited High School Contest. The announcement today coincides with National School Spirit Day, which was recognized by Congress last year.
“Our students feel connected to Vista Murrieta and have an engrained sense of school pride,” said Mick Wager, Principal of Vista Murrieta, “The family atmosphere and sense of community is apparent and genuine.”
High schools across the country were invited to enter the contest, which called for each school to submit a 90-second video, a 500-word essay, two letters of recommendation and several photos demonstrating its school spirit. High schools from 33 states were represented in the contest. Vista Murrieta’s video submission won based on a nationwide vote and included footage from games, pep rallies, and student activities that epitomize a robust school spirit environment that seeks to include all students. Vista Murrieta estimates that 85% of their students are involved in at least one activity, club or sport, and their video was a true testament to the power of school spirit and its effects on high school students.
To view the multimedia release go to:
http://www.multivu.com/players/English/7636151-varsity-brands-vista-murrieta-award/
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) presented today at a symposium during the World Diabetes Congress of the International Diabetes Federation (IDF), show that only 29% of people with diabetes report that their healthcare team ask for their input when making their treatment plans. Furthermore, only 33% said they were encouraged by their healthcare professional to ask questions in the consultation.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64152-novo-nordisk-diabetes-report-doctor-treatment
Bloomberg Government's "The Digital Trust: Securing Commerce," a five-city tour underwritten by Visa Inc., culminates in Washington, DC on March 26. Business leaders and government officials join Bloomberg Government to discuss ideas and principles learned in this cross-country conversation--redefining the bonds of trust and cooperation between retailers, regulators, Congress and consumers in a new era of digital commerce.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7371431-bloomberg-visa-the-digital-trust-securingcommerce/
In the U.S., approximately 159,000 women are living with metastatic breast cancer. To raise awareness of Metastatic Breast Cancer Awareness Day on October 13, MedImmune Specialty Care Division of AstraZeneca (NYSE: AZN) is launching the My+Story online resource center, which highlights the needs of women living with metastatic breast cancer and calls attention to metastatic disease as a key component of October’s National Breast Cancer Awareness Month. Metastatic Breast Cancer Awareness Day was officially recognized by the U.S. Congress in 2009, following a grassroots awareness effort led by members of the Metastatic Breast Cancer Network (MBCN).
To view Multimedia News Release, go to http://www.multivu.com/mnr/63080-astrazeneca-metastatic-breast-cancer-awareness
Nearly three in four American voters (74 percent) favor increasing federal funding for cancer research, according to the results of a new national survey conducted on behalf of the American Association for Cancer Research (AACR). The survey results were released today in conjunction with the AACR’s fifth annual Cancer Progress Report. The report highlights how federally funded research can power progress against cancer and urges Congress and the administration to implement a strategy for providing annual budget increases of at least 7 percent for the National Institutes of Health (NIH), National Cancer Institute (NCI), and U.S. Food and Drug Administration (FDA) in fiscal year 2016 and thereafter.
The national survey, which was conducted by Hart Research Associates and Public Opinion Strategies, shows that five out of every six voters recognize what the AACR Cancer Progress Report 2015 details: that progress is being made against cancer.
To view the multimedia release go to:
http://www.multivu.com/players/English/7613551-aacr-cancer-research-survey/
